scholarly journals Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections

2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Renato Santos Laboissiere ◽  
Marcelo Araújo Buzelin ◽  
Débora Balabram ◽  
Marina De Brot ◽  
Cristiana Buzelin Nunes ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Clinicopathological Features ◽  
Her2 Status ◽  
Tissue Sections

scholarly journals Clinicopathological significance of primitive phenotypes in early gastric cancer with differentiated histology

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Zhi-Yi Zhou ◽  
Jie Sun ◽  
Qing Guo ◽  
Hai-Bin Zhao ◽  
Zhi-Hua Zhou
Keyword(s):  
Gastric Cancer ◽  
Risk Factor ◽  
Early Gastric Cancer ◽  
Endoscopic Resection ◽  
Independent Risk Factor ◽  
Lymphatic Invasion ◽  
Clinicopathological Features ◽  
Surgical Operation ◽  
Tissue Sections ◽  
Clinicopathological Significance

Abstract Background Certain gastric cancers exhibit some primitive phenotypes, which may indicate a high malignancy. In histologically differentiated early gastric cancer (EGC), the presence and the clinicopathological significance of the primitive phenotype remain unclear. Methods Using immunohistochemical staining we detected the expression of three primitive phenotypic markers SALL4, Glypican-3(GPC3), and AFP in whole tissue sections of differentiated EGC (gastrectomy specimens, n = 302). For those cases with primitive phenotypes, we analyzed their clinicopathological features and evaluated whether the criteria for endoscopic resection were met. Results We found that 9.3% (28/302) of all differentiated EGC cases have primitive phenotypes, and most of these cases (25/28) exhibit a histomorphology similar to conventional differentiated EGC. Patients with primitive phenotypes had a deeper invasion, a higher rate of ulcer and lymphatic invasion than cases without primitive phenotype. Moreover, patients with primitive phenotypes displayed a significantly higher frequency of LNM than those without (57.1% vs 8.8%, P < 0.001). Multivariate analysis revealed that presence of primitive phenotypes was an independent risk factor for LNM (P = 0.001, HR 6.977, 95% CI: 2.199–22.138). Interestingly, we found 2 cases with primitive phenotypes developed LNM, and they both met the expanded indications of endoscopic resection for differentiated EGC. Conclusions A small number of differentiated EGC have primitive phenotypes, which were closely related to LNM and were an independent risk factor for LNM. Given its highly aggressive behavior, differentiated EGC with primitive phenotypes should be evaluated with stricter criteria before endoscopic resection, or considered to give an additional surgical operation after endoscopic resection.

Impact of screening survey of gastric cancer on clinicopathological features and survival: Retrospective study at a single institution

Surgery ◽  
2000 ◽  
Vol 128 (1) ◽  
pp. 41-47 ◽  
Author(s):  
Hirofumi Kubota ◽  
Tsukasa Kotoh ◽  
Reiko Masunaga ◽  
Dipok Kumar Dhar ◽  
Muneaki Shibakita ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Clinicopathological Features ◽  
Single Institution ◽  
Screening Survey

The impact of single-hetero UGT1A1 on clinical outcomes of irinotecan monotherapy in gastric cancer after fluoropyrimidine, platinum, and taxanes: Multicenter retrospective study.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 296-296
Author(s):  
Ken Ito ◽  
Yoshito Komatsu ◽  
Satoshi Yuki ◽  
Shintaro Nakano ◽  
Hiroshi Nakatsumi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Treatment Guidelines ◽  
Performance Status ◽  
Dose Intensity ◽  
Progression Free Survival ◽  
Her2 Status ◽  
Gastric Cancer Treatment ◽  
Third Line ◽  
The Impact

296 Background: Japanese gastric cancer treatment guidelines (5th edition) recommend irinotecan (IRI) after fluoropyrimidine, platinum and taxanes as a third line chemotherapy. We previously reported that patients with UGT1A1 single heterozygous (SH) had significantly high frequency of severe hematological adverse events (AEs) compared to patients with UGT1A1 wild type (WT) in IRI monotherapy for advanced gastric cancer (AGC). However, it remains unclear that UGT1A1 SH affect efficacy and safety of IRI after fluoropyrimidine, platinum and taxanes compared to WT as a salvage line. Methods: We retrospectively analyzed the clinical data of patients who received IRI monotherapy after fluoropyrimidine, platinum and taxanes in the multi-institutional retrospective study. From January 2010 to December 2017, 69 eligible patients were registered from 8 centers in Japan. Results: Forty one patients with UGT1A1 WT and 28 patients with UGT1A1 SH were included in this study. In WT/SH patients, performance status 0/1/≥2 was 12/25/4 and 5/17/6, treatment line 3rd/4th or later was 33/8 and 26/2, HER2 status positive/negative was 12/29 and 5/23, respectively. In WT/SH patients, rate of initial dose reduction was 22 and 28% (P = 0.363), median relative dose intensity (RDI) was 82% and 80% (P = 0.309). Of 88 patients who have measurable lesions, the overall response rate (ORR) was 5.7% and 4.2% (P = 1.000), disease control rate (DCR) was 54% and 38% (P = 0.289). Median progression free survival was 3.2 and 2.1 months (HR 0.607, P = 0.058) and median overall survival from initial day of IRI monotherapy was 10.0 and 7.0 months (HR 0.618 P = 0.086). In WT/SH patients, severe hematological AEs (≥G3) were observed more frequently in patients with UGT1A1 SH (WT: 43% and SH: 68%, P = 0.050), although frequency of severe non-hematological AEs (≥G3) were not significantly different in both groups (13% and 25%, P = 0.211). Conclusions: Compared to UGT1A1 WT, UGT1A1 SH status may be associated with poor efficacy and be a risk factor of higher frequency of severe hematological AEs.

Clinicopathologic significance of HER2 expression in gastric cancer: A retrospective study in Indian population.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15143-e15143
Author(s):  
Sudheer Reddy Kataru ◽  
Venkata Sampath Vankamamidi ◽  
Amit Kumar Chowhan ◽  
Meenakshisundaram Manickavasagam ◽  
Khajjayam Radhakrishna ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Indian Population ◽  
Smoking Status ◽  
Rank Test ◽  
Her2 Status ◽  
Published Data ◽  
Her2 Expression ◽  
Her2 Gene ◽  
Kaplan Meier

e15143 Background: Gastric cancer is the second most common cause of cancer related death worldwide. HER2 expression is an important biomarker for identifying patients who could respond to targeted therapy. The purpose of this study was to evaluate the frequency of HER2 expression and its clinicopathological significance in Indian population with gastric cancer. Methods: In this retrospective study, clinicopathological details and formalin fixed embedded tissue from patients with gastric and gastro-esophageal junction Adenocarcinoma of all stages from August 2009 to January 2012 were collected. HER2 status in the tissue was evaluated by the validated methods. IHC (Immunohistochemistry) scores of 3+ were considered positive, 2+ equivocal, 1+ and 0 negative for HER2. Equivocal staining was further evaluated with FISH (Fluorescence In-situ Hybridization) testing. The significance of HER2 expression was correlated with epidemiological, clinical, pathological and biochemical parameters using Pearson’s test. Progression free survivals (PFS) were compared using Log Rank test (Mantel-Cox). Kaplan-Meier curves were determined for PFS. SPSS version 17.0 was used for statistical analysis. Results: We studied 135 patients, of which IHC for HER2 was 3+ in 8.8%, 2+ in 10.4%, 1+ in 8.9% and zero in 71.9%. Among HER2 equivocal samples (n=14), FISH showed HER2 gene amplification in 14.2%. HER2 status was negative in 89.6% and positive in 10.4%.HER2 status significantly correlated with stage (p=0.03), smoking status (p=0.022) and not correlated with Age, Gender, Site, Lauren’s classification, Albumin, Hemoglobin. HER2 negative patients have better PFS (13.1 versus 7.1 months; p=0.005) and the levels of HER2 expression significantly influenced the PFS (p=0.006).Median PFS in patients with 3+, 2+, 1+ and zero IHC scores were 8.2, 8.8, 9.3, and 14.2 months respectively. Conclusions: The frequency of HER2 expression in gastric cancer in Indian population is comparable to the published data. HER2 in Gastric cancer serves as a prognostic marker.

scholarly journals Clinicopathological features of gastric cancer in young patients; Multicenter retrospective study

2017 ◽  
Vol 28 ◽  
pp. ix97
Author(s):  
Yoshiyasu Kono ◽  
Hiromitsu Kanzaki ◽  
Masahiro Takatani ◽  
Junichirou Nasu ◽  
Ryuta Takenaka ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Young Patients ◽  
Clinicopathological Features

scholarly journals Association between Her2/neu status in colorectal carcinoma and clinicopathological features: a retrospective study using whole – tissue sections

2018 ◽  
Vol 69 (2) ◽  
pp. 143-149
Author(s):  
Aydan Kılıçarslan ◽  
Hayriye Tatli Dogan ◽  
Nuran Süngü ◽  
Mehmet Dogan ◽  
Abdussamet Yalcin ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Colorectal Carcinoma ◽  
Clinicopathological Features ◽  
Tissue Sections

scholarly journals The Clinicopathological Features and Staging at Presentation of Gastric Cancer: A Single-Center Retrospective Study

2020 ◽  
Vol 06 (03) ◽  
pp. 120-126
Author(s):  
Syn Yi Chong ◽  
Soo Fan Ang
Keyword(s):  
Gastric Cancer ◽  
Weight Loss ◽  
Retrospective Study ◽  
Time Delay ◽  
Poor Prognosis ◽  
Stage Iv ◽  
Clinicopathological Features ◽  
Single Center ◽  
Distal Stomach ◽  
Specific Symptom

Abstract Introduction Gastric cancer (GC) is the third leading cause of cancer death, with most patients diagnosed at a later stage, with distant metastasis at the time of presentation, contributing to poor prognosis. GC has been associated with nonspecific clinical presentations, which cause a time delay for patients to seek for medical advice. This study aims to identify the clinicopathological features of GC patients and correlate time delay of the diagnosis to the staging of the disease. Materials and Methods This is a single-center retrospective study of GC patients diagnosed from January 2012 to December 2018. All relevant data of GC patient diagnosed during this time period were extracted from the patients’ case notes. Results A total of 69 GC patients were included in this study, with male preponderance and mean age of 62 years old. The top three symptoms presented are dyspepsia or ingestion (47.8%), weight loss (43.5%), and nausea or vomiting (33.3%). The mean time delay was 3.7 months. Patients presented with weight loss have a significantly longer average time delay of 4.88 months. Most tumor lesion was found at the distal stomach (43.5%), while 74.5% tested negative for Helicobacter pylori. Most patients were diagnosed at Stage IV (52.6%) and Stage III (36.8%) of the disease, with poorly differentiated (67.7%) histological features which have poor prognosis. Discussion and Conclusion No evidence of specific symptom or combination of symptoms predicts higher risk of GC. Regardless of the number of symptoms presented or the time delay, most GC patients were diagnosed at later stage of the disease. The study shows the importance of GC screening in Malaysia to ensure early detection, even before a symptom presented.

IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status

2014 ◽  
Vol 140 (12) ◽  
pp. 2163-2168 ◽  
Author(s):  
Emanuel Adelino M. Damasceno ◽  
Fabiana Pirani Carneiro ◽  
Albino Verçosa de Magalhães ◽  
Marcos de Vasconcelos Carneiro ◽  
Gustavo Henrique Soares Takano ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinicopathological Features ◽  
Her2 Status

scholarly journals Significance of aquaporins’ expression in the prognosis of gastric cancer

2018 ◽  
Vol 38 (3) ◽  
Author(s):  
Saroj Thapa ◽  
Mandika Chetry ◽  
Kaiyu Huang ◽  
Yangpei Peng ◽  
Jinsheng Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Mrna Expression ◽  
Cancer Patients ◽  
Expression Profiles ◽  
Prognostic Significance ◽  
Cancer Biomarker ◽  
Clinicopathological Features ◽  
Her2 Status ◽  
Aberrant Expression ◽  
Gastric Cancer Patients

Gastric carcinoma is one of the most lethal malignancy at present with leading cause of cancer-related deaths worldwide. Aquaporins (AQPs) are a family of small, integral membrane proteins, which have been evidenced to play a crucial role in cell migration and proliferation of different cancer cells including gastric cancers. However, the aberrant expression of specific AQPs and its correlation to detect predictive and prognostic significance in gastric cancer remains elusive. In the present study, we comprehensively explored immunohistochemistry based map of protein expression profiles in normal tissues, cancer and cell lines from publicly available Human Protein Atlas (HPA) database. Moreover, to improve our understanding of general gastric biology and guide to find novel predictive prognostic gastric cancer biomarker, we also retrieved ‘The Kaplan–Meier plotter’ (KM plotter) online database with specific AQPs mRNA to overall survival (OS) in different clinicopathological features. We revealed that ubiquitous expression of AQPs protein can be effective tools to generate gastric cancer biomarker. Furthermore, high level AQP3, AQP9, and AQP11 mRNA expression were correlated with better OS in all gastric patients, whereas AQP0, AQP1, AQP4, AQP5, AQP6, AQP8, and AQP10 mRNA expression were associated with poor OS. With regard to the clinicopathological features including Laurens classification, clinical stage, human epidermal growth factor receptor 2 (HER2) status, and different treatment strategy, we could illustrate significant role of individual AQP mRNA expression in the prognosis of gastric cancer patients. Thus, our results indicated that AQP’s protein and mRNA expression in gastric cancer patients provide effective role to predict prognosis and act as an essential agent to therapeutic strategy.

Sign in / Sign up

Export Citation Format

Share Document